[PDF][PDF] Sorafenib-irinotecan sequential therapy augmented the anti-tumor efficacy of monotherapy in hepatocellular carcinoma cells HepG2
HepG2 cells were exposed to sorafenib, irinotecan, and oxaliplatin and then subjected to
MTT assay to determine chemosensitivity. Flow cytometry was used to examine cell cycle …
MTT assay to determine chemosensitivity. Flow cytometry was used to examine cell cycle …
Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402
N Li, Y Zhang, T Wu, M Li - Ai Zheng= Aizheng= Chinese Journal of …, 2009 - europepmc.org
Methods BEL-7402 cells were treated with sorafenib or paclitaxel alone or in three different
schedules: sorafenib was give prior to, after, or simultaneously with paclitaxel. The half …
schedules: sorafenib was give prior to, after, or simultaneously with paclitaxel. The half …
Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro
FS Chen, YZ Cui, RC Luo, J Wu… - Nan Fang yi ke da xue xue …, 2008 - europepmc.org
Objective To investigate the inhibitory effect of sorafenib in combination with cisplatin (DDP)
on the proliferation of hepatocellular carcinoma cells and explore the molecular …
on the proliferation of hepatocellular carcinoma cells and explore the molecular …
Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media
M Tomizawa, F Shinozaki… - Experimental and …, 2010 - spandidos-publications.com
To suppress the invasion of hepatocellular carcinoma (HCC) cells into surrounding
connective tissues during metastasis, we investigated the usefulness of sorafenib. In order to …
connective tissues during metastasis, we investigated the usefulness of sorafenib. In order to …
Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism
LF Deng, YH Wang, QA Jia, ZG Ren… - Zhonghua gan Zang …, 2013 - europepmc.org
Objective To investigate the anti-cancer efficacy and mechanism of sorafenib and 5-
fluorouracil (5-FU) therapy in vitro using the HCC cell line MHCCLM3. Methods The effects …
fluorouracil (5-FU) therapy in vitro using the HCC cell line MHCCLM3. Methods The effects …
[HTML][HTML] Synergistic antitumor effect of sorafenib in combination with ATM inhibitor in hepatocellular carcinoma cells
J Liu, Y Liu, L Meng, B Ji, D Yang - International Journal of Medical …, 2017 - ncbi.nlm.nih.gov
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …
Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells
X Yao, C Zhao, H Yin, KW Wang, J Gao - Acta Pharmacologica Sinica, 2020 - nature.com
Sorafenib is currently the standard chemotherapy drug for treatment of advanced
hepatocellular carcinoma (HCC). But its efficacy requires improvement, it is imperative to …
hepatocellular carcinoma (HCC). But its efficacy requires improvement, it is imperative to …
Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor
NE El-Ashmawy, EG Khedr, HA El-Bahrawy… - Clinical and …, 2017 - Springer
Although sorafenib was approved as antiangiogenic agent in case of hepatocellular
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …
Research advances in sorafenib-induced apoptotic signaling pathways in liver cancer cells
Z ChaoYa, L ZaiMing - 临床肝胆病杂志, 2016 - lcgdbzz.org
Currently, sorafenib is the multi-target inhibitor for the treatment of advanced primary liver
cancer, and can effectively prolong the progression-free survival and overall survival in …
cancer, and can effectively prolong the progression-free survival and overall survival in …
Coadministration of sorafenib with adriamycin inhibits cell proliferation in hepatocellular carcinoma cells HepG2.
SWH Shi WeiHong, BYH Bian YongHua… - 2011 - cabidigitallibrary.org
HepG2 cells were treated with different concentrations of sorafenib or adriamycin alone or
their combination to investigate the inhibitory effect of sorafenib in combination with …
their combination to investigate the inhibitory effect of sorafenib in combination with …